Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Scynexis Inc chart...

About the Company

scynexis, inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. we are developing our lead product candidate, scy-078, a novel antifungal in phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.

Exchange

NASDAQ

Website

http://www.scynexis.com/

$0M

Total Revenue

81

Employees

$53M

Market Capitalization

0.94

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $SCYX News

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

2h ago, source:

SCY-247’s IND-enabling activities continue to advance with initiation of Phase I anticipated in the second half of 2024 Data analysis for the FURI study is ongoing; top line data from the CARES study ...

SCYNEXIS, Inc.

3mon ago, source: CNN

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections ...

Scynexis files patent for treatment of fungal infections with enfumafungin derivative triterpenoids

2d ago, source: Pharmaceutical Technology

Discover Scynexis Inc.'s patent for enfumafungin derivative triterpenoid antifungal compounds targeting fungal infections in low pH environments. Learn about the innovative treatment options for yeast ...

GSK Bets On Scynexis' FDA-Approved Antifungal Drug For Over $500M In Bio Bucks

12mon ago, source: Hosted on MSN

Scynexis is due to get $245.5 million in development, regulatory and commercial milestones there — with a separate $15 million tied to an FDA approval. Sales-related milestones add up to another ...

SCYNEXIS, Inc. (SCYX) Stock Historical Prices & Data - Yahoo Finance

5d ago, source: Yahoo Finance

*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

Sweet Baby Inc. Doesn’t Do What Some Gamers Think It Does

22d ago, source: Kotaku

Sweet Baby Inc. is not the largest narrative design company in the games industry. Nor is it solely responsible for the characters and stories in recent high-profile releases like Alan Wake 2 ...

CGTX Cognition Therapeutics, Inc.

1d ago, source: Seeking Alpha

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and ...

SCYNEXIS Inc.

1mon ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

SCYNEXIS, Inc. (SCYX)

16d ago, source: Yahoo Finance

*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...